We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

81 hedge funds and large institutions have $431M invested in Xenon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $308M → $431M (+$123M)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

1% more funds holding

Funds holding: 80 → 81 (+1)

0.25% more ownership

Funds ownership: 79.79% → 80.04% (+0.25%)

Holders
81
Holders Change
+1
Holders Change %
+1.25%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
25
Reduced
21
Closed
8
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
+$4.39M
2
BlackRock
BlackRock
New York
+$4.1M
3
Millennium Management
Millennium Management
New York
+$3.48M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.37M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$910K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$6.64M
2
EAM
Eventide Asset Management
Massachusetts
-$2.85M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.81M
4
ACP
Acuta Capital Partners
California
-$2.57M
5
AS
Altshuler Shaham
Israel
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$2.83M -$100K -8,573 -4%
AGA
27
Altrinsic Global Advisors
Connecticut
$2.62M – – –
GIM
28
Granahan Investment Management
Massachusetts
$2.36M -$63K -5,383 -3%
GPCM
29
Granite Point Capital Management
Massachusetts
$2.14M -$26.9K -2,300 -2%
Goldman Sachs
30
Goldman Sachs
New York
$2.12M +$889K +75,995 +123%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.51M -$84.2K -7,200 -7%
Vanguard Group
32
Vanguard Group
Pennsylvania
$1.5M +$31.2K +2,670 +3%
State Street
33
State Street
Massachusetts
$1.44M +$44.9K +3,839 +4%
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$1.24M +$910K +77,787 +1,556%
ACP
35
Acuta Capital Partners
California
$1.23M -$2.57M -220,000 -73%
Acadian Asset Management
36
Acadian Asset Management
Massachusetts
$1.19M -$62.7K -5,359 -6%
SSA
37
Schonfeld Strategic Advisors
New York
$1.12M +$117K +10,000 +16%
Citadel Advisors
38
Citadel Advisors
Florida
$1.1M -$2.81M -240,132 -77%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$1.07M -$93.5K -7,988 -10%
AA
40
ALPS Advisors
Colorado
$973K +$218K +18,630 +42%
Swiss National Bank
41
Swiss National Bank
Switzerland
$961K – – –
Two Sigma Investments
42
Two Sigma Investments
New York
$778K +$6.74K +576 +1%
Northern Trust
43
Northern Trust
Illinois
$717K -$184K -15,731 -25%
PNC Financial Services Group
44
PNC Financial Services Group
Pennsylvania
$703K – – –
BFM
45
Boothbay Fund Management
New York
$654K +$70.1K +5,995 +16%
SC
46
Scotia Capital
Ontario, Canada
$629K -$9.79K -837 -2%
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$629K +$667 +57 +0.1%
Deutsche Bank
48
Deutsche Bank
Germany
$470K +$597 +51 +0.2%
QSS
49
Quantitative Systematic Strategies
Florida
$450K +$203K +17,330 +145%
AC
50
Athanor Capital
New York
$410K +$24.1K +2,060 +8%
1
2
3 4

XENE Hedge Fund Activity: Q4 2020 in Review

81 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2020, worth a combined $431M — up 40% from $308M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new XENE positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was Ghost Tree Capital, adding an estimated $4.39M. The largest seller was Boxer Capital, exiting entirely with an estimated $6.64M sold.

  • 81 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2020, up from 80 in Q3 2020.
  • Funds reported $431M of Xenon Pharmaceuticals stock for Q4 2020, up 40% quarter-over-quarter.
  • 10 funds opened new Xenon Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +2 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2020 was Ghost Tree Capital, an estimated $4.39M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2020 was Boxer Capital, an estimated $6.64M sold.

Based on aggregated 13F filings for Q4 2020.